Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Real-world outcomes of mRCC in the current IO & TKI era

Neil Shah • 18 Feb 2022
GU Cancers 2022
Genitourinary Cancer Kidney Cancer Axitinib Ipilimumab Nivolumab Pembrolizumab

Neil Shah, MBBS, Memorial Sloan Kettering Cancer Center, New York City, NY, provides an overview of real-world clinical outcomes of the use of immuno-oncology (IO) agents and tyrosine kinase inhibitors (TKIs) for the management of US patients with metastatic renal cell carcinoma (mRCC). In this real-world study, longer treatment exposure was noted in patient receiving pembrolizumab + axitinib compared to ipilimumab + nivolumab or TKI monotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

More from Neil Shah

Challenges in utilizing big data in oncology research
1:18
Challenges in utilizing big data in oncology research
Neil Shah • 6 Jun 2023
Challenges and solutions in managing big data in oncology
1:13
Challenges and solutions in managing big data in oncology
Neil Shah • 4 Jun 2023
Overcoming the limitations encountered when working with large-scale oncology datasets
1:07
Overcoming the limitations encountered when working with large-scale oncology datasets
Neil Shah • 4 Jun 2023
Big data in oncology: challenges and solutions
3:23
Big data in oncology: challenges and solutions
Neil Shah • 4 Jun 2023

Related Videos

Therapeutic strategies to induce adaptive NK cells and improve outcomes in NMIBC
1:29
Therapeutic strategies to induce adaptive NK cells and improve outcomes in NMIBC
Bérengère Salomé • 26 Oct 2026
CMV-associated adaptive NK cells influence response to IO in NMIBC
1:52
CMV-associated adaptive NK cells influence response to IO in NMIBC
Bérengère Salomé • 26 Oct 2026
Combination therapy with AR-targeted and PSMA-targeted agents in prostate cancer
1:25
Combination therapy with AR-targeted and PSMA-targeted agents in prostate cancer
Alice Bernard-Tessier • 26 Oct 2026
Mechanisms of resistance to ARPIs in prostate cancer
0:55
Mechanisms of resistance to ARPIs in prostate cancer
Alice Bernard-Tessier • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals